Uni-Bio Science Group Limited

690 KYG9198H1406

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:03 2024-05-23 am EDT			5-day change	1st Jan Change
0.074 ^HKD	+1.37%		-3.90%	+2.78%

Mar. 27	Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 14	Uni-Bio Science's Profit to Climb in 2023	MT

Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

August 09, 2021 at 05:08 am EDT

Uni-Bio Science Group Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, a net profit of the Group for the six months ended 30 June 2021 is expected to be recorded, as compared with a net loss of the Group for the six months ended 30 June 2020.

Latest news about Uni-Bio Science Group Limited

Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Uni-Bio Science's Profit to Climb in 2023	Feb. 14	MT
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 December 2023	Feb. 13	CI
Chinese Regulator NMPA Accepts Uni-Bio's Marketing Application for Eye Drops	Jan. 23	MT
Uni-Bio Science Group Limited Announces the Acceptance of its Marketing Application for Diquafosol Sodium Eye Drops by the China National Medical Products Administration	Jan. 23	CI
China Grants Uni-Bio Science's Injection for Orthopedic Diseases	Jan. 22	MT
Uni-Bio Science Group Limited Announces Approval of Marketing Application of Bogutai (Teriparatide Injection) by the China National Medical Products Administration	Jan. 21	CI
Uni-Bio Science Group Limited commences an Equity Buyback for 636,476,815 shares, representing 10% of its issued share capital, under the authorization approved on May 19, 2023.	Dec. 13	CI
Uni-Bio Science Group Limited Announces the Resignation of Ms. Zhang Yanfen as Executive Director	Nov. 15	CI
Uni-Bio Science's Unit Grants 7.2 Million Yuan Loan to Taili Biomedical Technology	23-09-18	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Uni-Bio Science Group Limited Appoints Zhang Yanfen as an Executive Director	23-08-11	CI
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Uni-Bio Science Group Limited Provides Financial Guidance for the Year Ended 31 December 2022	23-03-06	CI
Uni-Bio Science Unit Renews Property Lease for Two Years	22-12-23	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Uni-Bio Science Group Limited Announces Marketing Application of Bogutai (Teriparatide Injection) Officially Accepted by the China National Medical Products Administration	22-06-28	CI
Uni-Bio Science CFO Resigns	22-04-01	MT
Uni-Bio Science Group Limited Announces Resignation of She Shi Bin Richard as Chief Financial Officer	22-03-31	CI
Uni-Bio Science Group Limited Announces Executive Changes	22-03-31	CI
Uni-Bio Science Narrows Loss on Higher Core Drugs Sales in 2021; Shares Rise 3%	22-03-22	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Uni-Bio Science Arm Signs R&D Deal for Medical Aesthetics Materials Development	22-01-05	MT
Uni-Bio Science Group Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Uni-Bio Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2021	21-08-11	CI

Chart Uni-Bio Science Group Limited

Duration

Period

More charts

Company Profile

Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-08-29 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
UNI-BIO SCIENCE GROUP LIMITED	+2.78%	57.64M
CSL LIMITED	-1.62%	89.22B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	40.49B
BIOGEN INC.	-15.73%	32.79B
UCB	+64.13%	26.23B
BIOMARIN PHARMACEUTICAL INC.	-21.28%	14.52B
INCYTE CORPORATION	-8.50%	13.09B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.07%	11.6B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.06%	11.5B
SWEDISH ORPHAN BIOVITRUM AB	+4.94%	8.82B

Biopharmaceuticals